Cover Page

Articles in Press

Past Issues

About actr

Manuscript Submission

AME Editing Service

Reprint & Permission

Advertising

Contact us

Commentary 
Revisiting neoadjuvant strategies in pancreatic cancer: insights from CASSANDRA
Rich Ericson King, Jennifer Jane Knox
AME Clinical Trials Review  
2026;
4:
54
.
 (25 October 2026) 
PDF Full Text (31) Peer Review File COI Form Open Access Get Permission
Commentary 
Validating IGF-1R targeted therapy for thyroid eye disease in Asian patients
Mirco Armenti, Mario Salvi
AME Clinical Trials Review  
2026;
4:
53
.
 (25 October 2026) 
PDF Full Text (36) Peer Review File COI Form Open Access Get Permission
Commentary 
Immediate or deferred non-culprit lesion pci in myocardial infarction: refining the timing of completeness
Francesco Gallo, Antonio Amadio, Marco Barbierato
AME Clinical Trials Review  
2026;
4:
52
.
 (25 October 2026) 
PDF Full Text (26) Peer Review File COI Form Open Access Get Permission
Commentary 
Interim insights into supplemental breast imaging for dense breasts: lessons from the BRAID trial
Federica Pediconi
AME Clinical Trials Review  
2026;
4:
51
.
 (25 October 2026) 
PDF Full Text (25) Peer Review File COI Form Open Access Get Permission
Commentary 
The role of low-dose atropine for childhood myopia: evaluating efficacy, durability and dosing
Andrzej Grzybowski
AME Clinical Trials Review  
2026;
4:
50
.
 (25 October 2026) 
PDF Full Text (24) Peer Review File COI Form Open Access Get Permission
Commentary 
Immune priming before intravesical bacillus Calmette-Guérin in non-muscle-invasive bladder cancer: lessons and perspectives from the RUTIVAC-1 trial
Mohamad Abou Chakra, Amanda A Myers, James A Brown, Kathryn A Marchetti, Michael A O’Donnell
AME Clinical Trials Review  
2026;
4:
49
.
 (25 October 2026) 
PDF Full Text (24) Peer Review File COI Form Open Access Get Permission
Commentary 
ENHANCE-ing outcomes in acute myeloid leukemia through immunotherapy: are we there yet?
Carl Shultz, Tajana Juranovic, Bhavana Bhatnagar
AME Clinical Trials Review  
2026;
4:
48
.
 (25 October 2026) 
PDF Full Text (52) Peer Review File COI Form Open Access Get Permission
Commentary 
The use of amustaline/glutathione pathogen-reduced red blood cells in cardiac surgery: a commentary
Daniel Bolliger
AME Clinical Trials Review  
2026;
4:
47
.
 (25 October 2026) 
PDF Full Text (29) Peer Review File COI Form Open Access Get Permission
Commentary 
Cyclic exclusive enteral nutrition and the nebulous diet landscape in Crohn’s disease
Levi Teigen, Julia S. Oliveira, Rachel Jacobsen, Byron P. Vaughn, Vikram J. Christian
AME Clinical Trials Review  
2026;
4:
46
.
 (25 October 2026) 
PDF Full Text (32) Peer Review File COI Form Open Access Get Permission
Commentary 
[177Lu]Lu-PSMA-617 and PD-1 blockade: lessons from the PRINCE trial
Daeun Shim, Douglas G. McNeel
AME Clinical Trials Review  
2026;
4:
45
.
 (25 October 2026) 
PDF Full Text (14) Peer Review File COI Form Open Access Get Permission
Review Article 
When a procedure fails an RCT, what exactly failed?—Interpreting provider-dependent procedure trials: a narrative review
Robert Groysman
AME Clinical Trials Review  
2026;
4:
44
.
 (25 October 2026) 
PDF Full Text (24) Reporting Checklist Peer Review File COI Form Open Access Get Permission
Editorial Commentary 
SURPASS-PEDS: clinical promise and priorities for future research on tirzepatide treatment for youth with type 2 diabetes
Wei Perng, Kristen Nadeau, Dana Dabelea
AME Clinical Trials Review  
2026;
4:
43
.
 (25 August 2026) 
PDF Full Text (361) Peer Review File COI Form Open Access Get Permission
Editorial Commentary 
Concurrent immune checkpoint blockade with chemoradiation: when more is less
Charles X. Wang, Sookyoung Joanna Kim, Megan E. Daly
AME Clinical Trials Review  
2026;
4:
42
.
 (25 August 2026) 
PDF Full Text (291) Peer Review File COI Form Open Access Get Permission
Editorial Commentary 
Lessons from PACIFIC-2 and the evolving landscape of unresectable stage III non-small cell lung cancer—when synergy blunts the benefit
Jairo Zuluaga, Juan Manuel Garzón-Dangond, Leonardo Rojas, Oscar Arrieta, Andrés F. Cardona
AME Clinical Trials Review  
2026;
4:
41
.
 (25 August 2026) 
PDF Full Text (379) Peer Review File COI Form Open Access Get Permission
Editorial Commentary 
Phacogoniotomy for advanced primary angle-closure glaucoma, from conceptual appeal to randomized evidence
Anand Kumar Pathak, Viney Gupta, Shikha Gupta
AME Clinical Trials Review  
2026;
4:
40
.
 (25 August 2026) 
PDF Full Text (289) Peer Review File COI Form Open Access Get Permission
Editorial Commentary 
Sunvozertinib redraws the map in EGFR ex20ins mutant non-small cell lung cancer
Huawei Chen, Hongmei Jiang, Qing Wu, Yu Xu
AME Clinical Trials Review  
2026;
4:
39
.
 (25 August 2026) 
PDF Full Text (396) Peer Review File COI Form Open Access Get Permission
Editorial Commentary 
Ribociclib in early breast cancer: interpreting the 4-year outcomes of the NATALEE trial
Prajakta P. Masurkar, Swarnali Goswami
AME Clinical Trials Review  
2026;
4:
38
.
 (25 August 2026) 
PDF Full Text (313) Peer Review File COI Form Open Access Get Permission
Editorial Commentary 
Balloon-based percutaneous coronary intervention in multilayer in-stent restenosis
Gianmaria Calamita, Pier Pasquale Leone, Azeem Latib
AME Clinical Trials Review  
2026;
4:
37
.
 (25 August 2026) 
PDF Full Text (256) Peer Review File COI Form Open Access Get Permission
Editorial Commentary 
Interpreting JCOG1409 (MONET): what does non-inferiority really mean for minimally invasive oesophagectomy?
Michael Patrick Achiam, Pieter de Heer
AME Clinical Trials Review  
2026;
4:
36
.
 (25 August 2026) 
PDF Full Text (219) Peer Review File COI Form Open Access Get Permission
Editorial Commentary 
HARMONi-6 trial: a further development in the management of advanced squamous non-small-cell lung cancer
Alessia Angela Guarino, Alfonso Fiorelli
AME Clinical Trials Review  
2026;
4:
35
.
 (25 August 2026) 
PDF Full Text (288) Peer Review File COI Form Open Access Get Permission
Editorial Commentary 
KEYNOTE-189 5-years update: setting a backbone for the next generation clinical research in advanced non-squamous non-small cell lung cancer without oncogenic addiction
Alessandra Merlini, Anis Cipi, Giorgia Ferrari, Paolo Bironzo
Published online: 11 June 2024
PDF Full Text (22300) Peer Review File COI Form Open Access Get Permission
Editorial Commentary 
Xaluritamig: a first step towards a new target, new mechanism for metastatic prostate cancer
Ruben Raychaudhuri, Michael T. Schweizer, Jessica E. Hawley, Lawrence Fong, Evan Y. Yu
Published online: 15 August 2024
PDF Full Text (18868) Peer Review File COI Form Open Access Get Permission
Review Article 
First-line treatment strategies and potential prognostic factors in patients with KRAS G12C-mutant non-small cell lung cancer
Malak Alharbi, Nour Nassour, Vaishali Deenadayalan, Grace K. Dy
Published online: 26 September 2025
PDF Full Text (17000) Peer Review File COI Form Open Access Get Permission
Editorial Commentary 
Assessing the UNICANCER-PRODIGE 23 trial through the lens of nonoperative management
Wini Zambare, Aron Bercz, J. Joshua Smith
Published online: 13 May 2025
PDF Full Text (14686) Peer Review File COI Form Open Access Get Permission
Editorial Commentary 
Yes to adjuvant osimertinib therapy in EGFR-mutated stage IB–IIIA non-small cell lung cancer post resection, but for how long? (ADAURA/NCT02511106)
Faustine Luo, Sai-Hong Ignatius Ou, Misako Nagasaka
Published online: 21 June 2024
PDF Full Text (14207) Peer Review File COI Form Open Access Get Permission
Editorial Commentary 
The Butterfly effect—will the MARIPOSA-2 study alter the trajectory of EGFR mutated non-small cell lung cancer (NSCLC)
Yuji Uehara, Aaron C. Tan
Published online: 06 June 2024
PDF Full Text (13650) Peer Review File COI Form Open Access Get Permission
Editorial Commentary 
Neoadjuvant FOLFIRINOX in resectable pancreatic cancer: impact of the NORPACT-1 trial
Eva Versteijne, Geertjan van Tienhoven, Anna M. E. Bruynzeel, Johanna W. Wilmink, Marc G. Besselink, Bas Groot Koerkamp; on behalf of the Dutch Pancreatic Cancer Group
Published online: 20 December 2024
PDF Full Text (12490) Peer Review File COI Form Open Access Get Permission
Editorial Commentary 
FLAURA in the real world: osimertinib in potentially trial-eligible and ineligible patients with EGFR-mutated advanced non-small cell lung cancer
Faustine X. Luo, Zhaohui Liao Arter, Sai-Hong Ignatius Ou, Misako Nagasaka
Published online: 04 December 2024
PDF Full Text (12359) Peer Review File COI Form Open Access Get Permission
Editorial Commentary 
Intracranial efficacy of adagrasib in patients with KRAS G12C mutated non-small cell lung cancer (NSCLC): are results KRYSTAL clear?
Anuja Abhyankar, Grace K. Dy
Published online: 21 August 2024
PDF Full Text (12151) Peer Review File COI Form Open Access Get Permission
Review Article 
Clinical advancements in total neoadjuvant therapy for locally advanced rectal cancer: a narrative review
Angelo Pirozzi, Celine Hoyek, Naohiro Okano, Leticia Assad Maia Sandoval, Binbin Zheng-Lin, Oluseyi Abidoye, Cody Eslinger, Mohamad Bassam Sonbol, Mitesh J. Borad, Tanios S. Bekaii-Saab
Published online: 26 September 2025
PDF Full Text (11291) Reporting Checklist Peer Review File COI Form Open Access Get Permission
Editorial Commentary 
Eradication of Helicobacter pylori and its impact on the incidence of gastric cancer
Luis Guilherme de Oliveira Silva, Fabian Fellipe Bueno Lemos, Fabrício Freire de Melo
Published online: 08 May 2025
PDF Full Text (11044) Peer Review File COI Form Open Access Get Permission
Editorial Commentary 
The optimum balance between efficacy and toxicity with different doses of trastuzumab deruxtecan in HER2 mutated non-small cell lung cancer in DESTINY-Lung02 trial
Saurav Verma, Jacques Raphael
Published online: 02 September 2024
PDF Full Text (10742) Peer Review File COI Form Open Access Get Permission
Editorial Commentary 
Immunotherapy as the new standard of care for advanced endometrial cancer
Giovanna Vieira Giannecchini, Martina Parenza Arenhardt, Andreia Cristina de Melo
Published online: 03 April 2025
PDF Full Text (10303) Peer Review File COI Form Open Access Get Permission
Editorial Commentary 
Post-CDK4/6i wars in HR+/HER2− breast cancer: is elacestrant a solid contender through the lens of precision oncology
Ünal Metin Tokat, Nalan Babacan, Mutlu Demiray
Published online: 01 July 2025
PDF Full Text (10078) Peer Review File COI Form Open Access Get Permission
Editorial Commentary 
Is zilebesiran a novel effective and uniquely administered agent for an expanding therapeutic armamentarium for blood pressure control?
John M. Flack
Published online: 24 February 2025
PDF Full Text (9501) Peer Review File COI Form Open Access Get Permission
Editorial Commentary 
Unpacking prostate-specific antigen dynamics and patient outcomes: insights from the ARASENS trial
Hayley Nicole Roberts, Corinne Maurice-Dror, Kim Nguyen Chi
Published online: 21 February 2025
PDF Full Text (9331) Peer Review File COI Form Open Access Get Permission
Review Article 
Recent updates in targeted therapy for advanced non-small cell lung cancer with actionable genomic alterations: a narrative review
Fangdi Sun, Joel W. Neal
Published online: 21 July 2025
PDF Full Text (9278) Reporting Checklist Peer Review File COI Form Open Access Get Permission
Review Article 
The role of minimal residual disease measurement in multiple myeloma
Bhavesh Mohan Lal, Nikhil Vojjala, Nikhila Sampath Kumar, Carolina Schinke
Published online: 26 September 2025
PDF Full Text (9051) Peer Review File COI Form Open Access Get Permission
Editorial Commentary 
Optimizing antiplatelet therapy after coronary artery bypass graft: selection, dosing, and duration
Lokeswara Rao Sajja, Pradeep Narayan, Sanjeeth Peter
Published online: 17 December 2024
PDF Full Text (9032) Peer Review File COI Form Open Access Get Permission
Editorial Commentary 
Induction therapy for acute myeloid leukemia: still nothing beyond 7+3?
Daniela Damiani, Mario Tiribelli
Published online: 20 June 2024
PDF Full Text (8849) Peer Review File COI Form Open Access Get Permission

Journal Highlight more

AME Clinical Trials Review (AME Clin Trials Rev; ACTR) is an international, open-access, peer-reviewed online journal, publishing commentaries on all phases of clinical trials, including but not limited to the design, conduct, analysis, regulation and ethics. It is dedicated to sharing insights of the key opinion leaders to stimulate thought and discussion in clinical trials and facilitate the translation of the findings of clinical trials from bench to bedside, and to clinical practice. More >>

Clinical Trials Education Channel

The Clinical Trials Education Channel aims to publish Review Article of high educational value that can guide the better understanding and practice of the whole cycle of clinical trials, including ethics, methodological design, analysis, reporting, appraisal, and supervision. More >>

Reviewers more

In 2026, ACTR reviewers continue to make outstanding contributions to the peer review process. More >>
In 2025, ACTR reviewers continue to make outstanding contributions to the peer review process. More >>

Announcement more

Join us at the IASLC 2026 World Conference on Lung Cancer

The IASLC 2026 World Conference on Lung Cancer (WCLC) is going to be held in Seoul, Republic of Korea from September 12th to 15th, 2026: https://wclc.iaslc.org/ More >>

ACTR Annual Report 2025

Greetings from Dr. Kaiping Zhang and the Editorial Office of AME Clinical Trials Review (ACTR). More >>

Join us at the 9th World Congress of Pediatric Cardiology & Cardiac Surgery

The 9th World Congress of Pediatric Cardiology & Cardiac Surgery (WCPCCS) is going to be held at the Hong Kong Convention and Exhibition Centre, Hong Kong, China from December 7 to... More >>

Indexing

AME Clinical Trials Review is indexed and covered by

Membership

Member since 2021

Publishing Information

AME Clinical Trials Review is published by AME Publishing Company

AME Publishing Company

AME Clinical Trials Review is published with support from Wolters Kluwer

Wolters Kluwer

Social Media